Herbert H. Loong

Central Ave
Central, HCW, Hong Kong Special Administrative Region

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 01, 2026

Lung cancer across borders: From molecular epidemiology to precision treatment strategies.

Lung cancer across borders: From molecular epidemiology to precision treatment strategies.

Journal: Therapeutic advances in medical oncology

Published: May 22, 2026

Cognitive complaints and their associations with role functioning limitations among adolescent and young adult cancer survivors in Hong Kong.

Cognitive complaints and their associations with role functioning limitations among adolescent and young adult cancer survivors in Hong Kong.

Journal: Asia-Pacific journal of oncology nursing

Published: April 30, 2026

Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced/metastatic NSCLC: insights from a multiregional steering committee.

Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced/metastatic NSCLC: insights from a multiregional steering committee.

Journal: Therapeutic advances in medical oncology

Published: April 24, 2026

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 24, 2026

Why are we still using cisplatin? : Rationale for the continued use of cisplatin in oncology.

Why are we still using cisplatin? : Rationale for the continued use of cisplatin in oncology.

Journal: Cancer chemotherapy and pharmacology

Published: January 09, 2026

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: October 17, 2025

Population-scale genomic medicine with the Hong Kong Genome Project.

Population-scale genomic medicine with the Hong Kong Genome Project.

Journal: Nature medicine

Published: September 09, 2025

Digital health interventions for psychological outcomes among adolescents and young adults with cancer: a systematic review and meta-analysis.

Digital health interventions for psychological outcomes among adolescents and young adults with cancer: a systematic review and meta-analysis.

Journal: NPJ digital medicine

Published: July 16, 2025

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.

Journal: Cancer discovery

Published: May 14, 2025

First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion-Positive NSCLC: A LIBRETTO-431 Subgroup Analysis.

First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion-Positive NSCLC: A LIBRETTO-431 Subgroup Analysis.

Journal: JTO clinical and research reports

Published: March 25, 2025

D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial.

D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial.

Journal: Nature medicine

Published: March 06, 2025

Showing 1-12 of 84

Last Updated: 09/26/2026